NCT00005762View on ClinicalTrials.gov

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2001

Study Completion Date

May 31, 2004

Conditions

HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Ritonavir

DRUG

Amprenavir

DRUG

Nelfinavir mesylate

DRUG

Efavirenz

DRUG

Saquinavir

Trial Locations (8)

37203

Vanderbilt Univ. Med. Ctr., AIDS Clinical Trials Ctr., Nashville

43210

The Ohio State University Medical Center, Columbus

80262

University of Colorado Hospital CRS, Aurora

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

98104

University of Washington AIDS CRS, Seattle

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

943055107

Stanford CRS, Palo Alto

Unknown

Johns Hopkins Adult AIDS CRS, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00005762 - Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers | Biotech Hunter | Biotech Hunter